Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 188 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacogenomics Clear all
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 19, 2026, 9:09 AM EDT
Active, not recruiting Phase 4 Interventional

Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

NCT02044497
View directory record Official record
Conditions
Pediatric Surgical Patient
Interventions
oral oxycodone
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 6 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

NCT02625207
View directory record Official record
Conditions
Healthy Subjects
Interventions
Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 19, 2026, 9:09 AM EDT
Completed No phase listed Observational

Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

NCT00890448
View directory record Official record
Conditions
Toxicity
Interventions
Pharmacogenomic whole blood sampling
Other
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Jacksonville, Florida • Jupiter, Florida • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - II (PARes-II)

NCT01894555
View directory record Official record
Conditions
Atherothrombosis
Interventions
Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 19, 2026, 9:09 AM EDT
Completed No phase listed Observational

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

NCT00005570
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenic Purpura
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 9:09 AM EDT
Enrolling by invitation No phase listed Observational

Assessing Concentrations of Methadone and Its Metabolites

NCT06835582
View directory record Official record
Conditions
Opioid Use Disorder, Pain
Interventions
Methadone
Drug
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 19, 2026, 9:09 AM EDT
Withdrawn Phase 4 Interventional

PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care

NCT00377143
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Warfarin Dosing
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 19, 2026, 9:09 AM EDT
Not listed Phase 4 Interventional

Evaluation of Pharmacogenomics Testing to Precision Prescriptions in Periodontal Patients

NCT05467436
View directory record Official record
Conditions
Oral Surgeries
Interventions
Local anesthetics, IV sedation drugs and analgesics.
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 19, 2026, 9:09 AM EDT
Not listed No phase listed Observational

Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting

NCT05053815
View directory record Official record
Conditions
Pharmacogenomics, Polypharmacy
Interventions
Pharmacogenomic Testing
Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 19, 2026, 9:09 AM EDT
Not listed No phase listed Observational

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

NCT01486524
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Sirius Genomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - I

NCT01815008
View directory record Official record
Conditions
Platelet Aggregation, Platelet Transcriptome, Coronary Artery Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated No phase listed Observational

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

NCT01427374
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Not applicable Interventional

Genotype-Guided Warfarin Therapy Trial

NCT00904293
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
Interventions
Genotype-guided dose determination, Non-genotype guided warfarin dosing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 19, 2026, 9:09 AM EDT
Completed No phase listed Observational

Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)

NCT01272531
View directory record Official record
Conditions
Bipolar Affective Disorder
Interventions
Mood stabilizer treatment
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 19, 2026, 9:09 AM EDT
Not listed No phase listed Observational

Pharmacist-led Interventions to Improve Medication Use

NCT05346770
View directory record Official record
Conditions
Pharmacogenomics, Old Age
Interventions
Behavioral Intervention, Diagnostic Test, Data Analysis
Behavioral · Diagnostic Test · Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 19, 2026, 9:09 AM EDT
Completed Phase 1 Interventional

Safety of Batracylin in Patients With Solid Tumors and Lymphomas

NCT00450502
View directory record Official record
Conditions
Neoplasms
Interventions
Batracylin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 19, 2026, 9:09 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

NCT01064466
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ETOPOSIDE - Usual, ETOPOSIDE - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Recruiting Phase 4 Interventional

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

NCT07158164
View directory record Official record
Conditions
Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Gastro-Intestinal Intraepithelial Neoplasia
Interventions
Fluorouracil injection, Xeloda
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacogenomics of GLP1 Receptor Agonists

NCT05762744
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 19, 2026, 9:09 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to GLP1R Agonists

NCT05071898
View directory record Official record
Conditions
Obesity, Diabetes Type 2
Interventions
Semaglutide Pen Injector [Ozempic]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Recruiting No phase listed Observational

Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities

NCT03225820
View directory record Official record
Conditions
Information Seeking Behavior
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 19, 2026, 9:09 AM EDT
Terminated No phase listed Observational

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

NCT00471653
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Thrombocytopenia
Interventions
temozolomide, comparative genomic hybridization, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Duarte, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 19, 2026, 9:09 AM EDT